Last reviewed · How we verify
NOX1416 and SOC
At a glance
| Generic name | NOX1416 and SOC |
|---|---|
| Also known as | ADVANOX |
| Sponsor | NOxy Health Products, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (PHASE1)
- NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOX1416 and SOC CI brief — competitive landscape report
- NOX1416 and SOC updates RSS · CI watch RSS
- NOxy Health Products, LLC portfolio CI